Characteristic | No. of Patients | APTX mRNA | BRCA1 mRNA | ERCC1 mRNA | ISG15 mRNA | Topo1 mRNA |
---|---|---|---|---|---|---|
 |  | mean ± SD | mean ± SD | mean ± SD | mean ± SD | mean ± SD |
Age, y | Â | Â | Â | Â | Â | Â |
 ≥ 63 | 91 (52%) | 4.81 ± 3.78 | 8.61 ± 5.73 | 15.28 ± 10.01 | 4.48 ± 3.69 | 8.03 ± 7.30 |
 < 63 | 84 (48%) | 4.09 ± 3.76 | 7.90 ± 5.95 | 14.75 ± 9.28 | 5.79 ± 6.90 | 7.47 ± 5.81 |
Sex | Â | Â | Â | Â | Â | Â |
 Male | 131 (75%) | 4.77 ± 3.33 | 8.41 ± 5.57 | 15.74 ± 10.19 | 5.54 ± 5.62 | 7.95 ± 7.17 |
 Female | 44 (25%) | 3.58 ± 3.29 | 7.92 ± 6.67 | 12.77 ± 7.30 | 3.53 ± 4.27* | 7.21 ± 4.62 |
Tumor Site | Â | Â | Â | Â | Â | Â |
 Distal stomach | 62 (35%) | 4.79 ± 2.87 | 8.97 ± 6.52 | 16.12 ± 10.36 | 7.05 ± 7.75 | 8.09 ± 5.93 |
 Proximal stomach | 70 (40%) | 4.16 ± 3.10 | 8.33 ± 5.72 | 13.97 ± 9.09 | 3.61 ± 2.64 | 7.40 ± 6.63 |
 Whole stomach | 43 (25%) | 4.60 ± 4.44 | 7.12 ± 4.74 | 15.31 ± 9.70 | 4.61 ± 3.43 | 7.06 ± 7.94 |
Stage | Â | Â | Â | Â | Â | Â |
 I | 20 (11%) | 4.25 ± 4.47 | 5.91 ± 3.40 | 13.40 ± 7.07 | 1.89 ± 0.83 | 5.89 ± 4.03 |
 II | 41 (23%) | 4.19 ± 3.01 | 8.58 ± 5.09 | 14.70 ± 9.56 | 6.76 ± 7.96 | 8.91 ± 6.35 |
 III | 110 (63%) | 4.66 ± 3.38 | 8.19 ± 5.75 | 15.56 ± 10.16 | 4.67 ± 4.01 | 7.70 ± 7.07 |
 IV | 4 (3%) | 4.20 ± 4.61 | 15.88 ± 17.90 | 11.01 ± 5.00 | 7.25 ± 6.33 | 4.03 ± 1.63 |
Histological grade | Â | Â | Â | Â | Â | Â |
 2 | 36 (21%) | 5.05 ± 3.54* | 10.97 ± 7.33 | 15.78 ± 9.52 | 4.86 ± 4.75 | 8.08 ± 6.61 |
 3 | 81 (46%) | 3.92 ± 3.55 | 7.81 ± 5.16 | 14.30 ± 9.64 | 3.68 ± 2.75 | 7.18 ± 6.08 |
 Mixed 1–2 | 6 (3%) | 3.63 ± 4.51 | 7.17 ± 2.13 | 15.17 ± 12.40 | 8.00 ± 8.94 | 8.42 ± 6.02 |
 Mixed 2–3 | 52 (30%) | 4.55 ± 2.53 | 7.06 ± 5.27 | 15.65 ± 9.96 | 7.16 ± 7.74 | 8.44 ± 7.18 |
Lymph node metastasis | Â | Â | Â | Â | Â | Â |
 No | 40 (23%) | 4.58 ± 3.39 | 8.70 ± 5.08 | 14.68 ± 7.31 | 5.97 ± 8.17 | 7.48 ± 4.47 |
 Yes | 135 (77%) | 4.46 ± 3.35 | 8.16 ± 6.05 | 15.16 ± 10.33 | 4.78 ± 4.12 | 7.87 ± 7.23 |